SeaBridge Investment Advisors LLC Buys 121 Shares of Stryker Co. (NYSE:SYK)

SeaBridge Investment Advisors LLC increased its stake in Stryker Co. (NYSE:SYK) by 1.9% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 6,470 shares of the medical technology company’s stock after purchasing an additional 121 shares during the period. SeaBridge Investment Advisors LLC’s holdings in Stryker were worth $2,330,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of SYK. Dunhill Financial LLC raised its position in shares of Stryker by 94.9% in the 3rd quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock valued at $27,000 after buying an additional 37 shares in the last quarter. Darwin Wealth Management LLC acquired a new position in Stryker during the third quarter valued at approximately $36,000. Crews Bank & Trust bought a new stake in Stryker during the fourth quarter worth $39,000. Hara Capital LLC acquired a new stake in shares of Stryker in the 3rd quarter valued at $42,000. Finally, HBW Advisory Services LLC acquired a new stake in shares of Stryker in the 3rd quarter valued at $42,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Stock Up 0.1 %

Shares of NYSE SYK opened at $390.90 on Friday. Stryker Co. has a 52-week low of $314.93 and a 52-week high of $406.19. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.22 and a current ratio of 1.91. The company’s 50 day moving average price is $376.68 and its 200-day moving average price is $362.81. The company has a market capitalization of $149.02 billion, a P/E ratio of 50.37, a price-to-earnings-growth ratio of 2.68 and a beta of 0.95.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, beating analysts’ consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.86%. During the same quarter in the previous year, the company earned $3.46 EPS. Equities analysts forecast that Stryker Co. will post 13.53 earnings per share for the current year.

Stryker Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Tuesday, December 31st were issued a $0.84 dividend. This is an increase from Stryker’s previous quarterly dividend of $0.80. This represents a $3.36 dividend on an annualized basis and a yield of 0.86%. The ex-dividend date was Tuesday, December 31st. Stryker’s payout ratio is presently 43.30%.

Insider Buying and Selling at Stryker

In other news, CEO Kevin Lobo sold 57,313 shares of the firm’s stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $368.70, for a total value of $21,131,303.10. Following the completion of the sale, the chief executive officer now directly owns 100,027 shares in the company, valued at $36,879,954.90. This trade represents a 36.43 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Insiders own 5.90% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on SYK. Wells Fargo & Company upped their price objective on Stryker from $427.00 to $435.00 and gave the stock an “overweight” rating in a research report on Wednesday. JMP Securities reissued a “market perform” rating on shares of Stryker in a report on Tuesday, January 7th. Piper Sandler reaffirmed an “overweight” rating and set a $420.00 price target (up from $380.00) on shares of Stryker in a report on Wednesday, October 30th. Barclays increased their price objective on shares of Stryker from $402.00 to $418.00 and gave the company an “overweight” rating in a research note on Thursday, October 31st. Finally, Citigroup boosted their target price on shares of Stryker from $411.00 to $450.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. Five research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $419.37.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.